PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-35.79%
Both companies show declining cash positions (-35.79% vs TRVN's -13.05%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-35.79%
Cash + STI yoy ≥ 1.5x TRVN's -21.55%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.27%
Above 1.5x TRVN's -1.01%. Michael Burry might investigate for potential short-term asset misclassification or risk.
-32.53%
≥ 1.5x TRVN's -20.63%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-2.15%
0.75-0.9x TRVN's -2.58%. Bill Ackman questions if competitor invests more heavily in future capacity.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.04%
50-75% of TRVN's -0.08%. Bruce Berkowitz notes relatively lower 'other assets' expansions.
-1.56%
0.5-0.75x TRVN's -2.23%. Martin Whitman wonders if there's insufficient reinvestment vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-28.33%
≥ 1.5x TRVN's -16.90%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-12.11%
Less than half of TRVN's -33.33%. David Dodd sees a more disciplined AP approach or lower volume.
-29.66%
Less than half of TRVN's -88.65%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
6.29%
Higher Deferred Revenue (Current) Growth compared to TRVN's zero value, indicating better performance.
100.00%
Less than half of TRVN's -155.06%. David Dodd sees fewer expansions in other current obligations.
-11.86%
Less than half of TRVN's -71.26%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x TRVN's -60.00%. Michael Burry suspects a looming risk from large additions to LT liabilities.
-7.08%
Above 1.5x TRVN's -2.19%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-11.32%
Less than half of TRVN's -39.38%. David Dodd sees far fewer liability expansions relative to competitor.
6.25%
1.1-1.25x TRVN's 5.32%. Bill Ackman questions if the firm is issuing more stock than competitor.
-2.72%
≥ 1.5x TRVN's -1.39%. David Dodd sees higher yoy retained profits than competitor.
100.00%
Less than half of TRVN's 200.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-46.50%
≥ 1.5x TRVN's -4.27%. David Dodd sees stronger capital base growth than competitor.
-28.33%
≥ 1.5x TRVN's -16.90%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-8.76%
Less than half of TRVN's -38.50%. David Dodd sees less overall debt expansion vs. competitor.
40.72%
Less than half of TRVN's -5.14%. David Dodd sees better deleveraging or stronger cash buildup than competitor.